ONYX-015 Enhances Radiation-Induced Death of Human Anaplastic Thyroid Carcinoma Cells(467 views) Portella G, Pacelli R, Libertini S, Cella L, Vecchio G, Salvatore M, Fusco A
J Clin Endocrinol Metab Journal Of Clinical Endocrinology And Metabolism (ISSN: 0021-972x), 2003 Oct 1; 88(10): 5027-5032.
Keywords: Adenovirus Vector, Dna Fragment, Doxorubicin, Onyx 015, Paclitaxel, Anaplastic Carcinoma, Anaplastic Thyroid Carcinoma, Antineoplastic Activity, Apoptosis, Article, Cancer Radiotherapy, Controlled Study, Cytopathogenic Effect, Cytotoxicity, Drug Potentiation, Human, Human Cell, Low Drug Dose, Nude Mouse, Priority Journal, Radiation Dose, Radiosensitivity, Tumor Xenograft, Virus Replication, Adenoviridae, Animals, Cell Death, Combined Modality Therapy, Dna Fragmentation, Mice, Radiation Tolerance, Thyroid Neoplasms, Tumor Cells, Cultured, Viral Vaccines, Xenograft Model Antitumor Assays, Mus Musculus,
Affiliations: *** IBB - CNR ***
Dipto. Biol. e Patol. Cell. e Molec., Univ. di Napoli Federico II, 80131 Naples, Italy
Dipto. Diagnostica Immagini R., Univ. di Napoli Federico II, 80131 Naples, Italy
References: Hedinger, C., Williams, E.D., Sobin, L.H., The WHO histological classification of thyroid tumours: A commentary on the second edition (1989) Cancer, 63, pp. 908-91
Wynford-Thomas, D., Origin and progression of thyroid epithelial tumours. Cellular and molecular mechanisms (1997) Horm Res, 47, pp. 145-157
Ain, K.B., Anaplastic thyroid carcinoma: A therapeutic challenge (1999) Semin Surg Oncol, 16, pp. 64-69
Bischott, J.R., Kirn, D.H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., McCormick, F., An adenovirus mutant that replicates selectively in p53 deficient human tumor cells (1996) Science, 274, pp. 373-376
Ries, S.J., Brandts, C.H., Chung, A.S., Biederer, C.H., Hann, B.C., Lipner, E.M., McCormick, F., Korn, W.M., Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015) (2000) Nat Med, 6, pp. 1128-1133
Nemunaitis, J., Ganly, I., Khuri, F., Arseneau, J., Kuhn, J., McCarty, T., Landers, S., Kirn, D., Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: A phase II trial (2000) Cancer Res, 15, pp. 6359-6366
Ito, T., Seyama, T., Mizuno, T., Tsuyama, N., Hayashi, T., Hayashi, Y., Dohi, K., Akiyama, M., Unique association of p53 mutations with undifferentiated but not differentiated carcinomas of the thyroid gland (1992) Cancer Res, 52, pp. 1369-1371
Fagin, J.A., Matsuo, K., Karmakar, A., Chen, D.L., Tang, S.H., Koeffler, H.P., High prevalence of mutations of p53 gene in poorly differentiated human thyroid carcinomas (1993) J Clin Invest, 91, pp. 179-184
Dobashi, Y., Sakamoto, A., Sugimura, H., Mernyei, M., Mori, M., Oyama, T., Machinami, R., Overexpression of p53 as a possible prognostic factor in human thyroid carcinoma (1993) Am J Surg Pathol, 17, pp. 375-381
Donghi, R., Longoni, A., Pilotti, S., Michieli, P., Della Porta, G., Pierotti, M.A., p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland (1993) J Clin Invest, 91, pp. 1753-1760
Matias-Guiu, X., Cuatrecasas, M., Musulen, E., Prat, J., p53 expression in anaplastic carcinomas arising from thyroid papillary carcinomas (1994) J Clin Pathol, 47, pp. 337-339
Fusco, A., Santoro, M., Human thyroid carcinogenesis (1997) Forum, pp. 214-229. , 7.2
Khuri, F.R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I.F., Romel, L., Gore, M., Kirn, D.H., A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer patients (2000) Nat Med, 6, pp. 879-885
Nemunaitis, J., Khuri, F., Ganly, I., Arseneau, J., Posner, M., Vokes, E., Kuhn, J., Kirn, D., Phase II trial of intratumoral administration of ONYX-015, a replicationselective adenovirus, in patients with refractory head and neck cancer (2001) J Clin Oncol, 19, pp. 289-298
Habib, N.A., Mitry, R.R., Sarraf, C.E., Habib, N.A., Mitry, R.R., Sarraf, C.E., Jiao, L.R., Jensen, S.L., Assessment of growth inhibition and morphological changes in in vitro and in vivo hepatocellular carcinoma models post treatment with dl1520 adenovirus (2002) Cancer Gene Ther, 9, pp. 414-420
Reid, T., Galanis, E., Abbruzzese, J., Sze, D., Wein, L.M., Andrews, J., Randlev, B., Kirn, D., Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): Phase II viral, immunologic, and clinical endpoints (2002) Cancer Res, 62, pp. 6070-6079
Mulvihill, S., Warren, R., Venook, A., Adler, A., Randlev, B., Heise, C., Kirn, D., Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: A phase I trial (2001) Gene Ther, 8, pp. 308-315
Portella, G., Scala, S., Vitagliano, D., Vecchio, G., Fusco, A., ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines (2002) J Clin Endocrinol Metab, 87, pp. 2525-2531
Nemunaitis, J., Cunningham, C., Buchanan, A., Blackburn, A., Edelman, G., Maples, P., Netto, G., Kirn, D., Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: Safety, feasibility and biological activity (2001) Gene Ther, 8, pp. 746-759
Heise, C., Sampson-Johannes, A., Williams, A., McCormick, F., Von Hoff, D.D., Kirn, D.H., ONYX-015, an aE1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents (1997) Nat Med, 3, pp. 639-1545
You, L., Yang, C., Jablons, D.M., ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients (2000) Cancer Res, 60, pp. 1009-1013
Pang, X.J., Hershman, M., Chung, M., Pekary, A.E., Characterization of tumor necrosis factor-α receptors in human and rat thyroid cells and regulation of the receptors by thyrotropin (1989) Endocrinology, 125, pp. 1783-1788
Ain, K.B., Tofiq, S., Taylor, K.D., Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo (1996) J Clin Endocrinol Metab, 81, pp. 3650-3653
Rogulski, K.R., Freytag, S.O., Zhang, K., Gilbert, J.D., Paielli, D.L., Kim, J.H., Heise, C.C., Kirn, D.H., In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy (2000) Cancer Res, 60, pp. 1193-1196
Yeung, S.J., Xu, G., Pan, J., Christgen, M., Bamiagis, A., Manumycin enhances the cytotoxix effect of paclitaxel on anaplastic thyroid carcinoma cells (2000) Cancer Res, 60, pp. 650-656
Xu, G., Pan, J., Martin, C., Yeung, S.J., Angiogenesis inhibition in the in vivo antineoplastic effect of manumycin and paclitaxel against anaplastic thyroid carcinoma (2001) J Clin Endocrinol Metab, 86, pp. 1769-1777
Scala, S., Portella, G., Fedele, M., Chiappetta, G., Fusco, A., Adenovirus-mediated suppression of HMGI (Y) protein synthesis as potential therapy of human malignant neoplasias (2000) Proc Nat Acad Sci USA, 97, pp. 4256-4261
Lowe, S.W., Ruley, H.E., Jacks, T., Housman, D.E., p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents (1993) Cell, 74, pp. 957-967
Shao, R., Karunagaran, D., Zhou, B.P., Li, K., Lo, S.S., Deng, J., Chiao, P., Hung, M.C., Inhibition of nuclear factor-KB activity is involved in E1A-mediated sensitization of radiation-induced apoptosis (1997) J Biol Chem, 272, pp. 32739-32742
Zhou, Z., Jia, S.F., Hung, M.C., Kleinerman, E.S., E1A sensitizes HER2/neu overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs (2001) Cancer Res, 61, pp. 3394-3398
Frisch, S., Mymryk, J., Adenovirus-5 E1A: Paradox and paradigm (2002) Nat Rev Mol Cell Biol, 6, pp. 441-452
Deng, J., Xia, W., Hung, M.C., Adenovirus 5 E1A-mediated tumor suppression associated with E1A-mediated apoptosis in vivo (1998) Oncogene, 17, pp. 2167-2175
Debbas, M., White, E., Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B (1993) Genes Dev, 7, pp. 546-554
Putzer, B.M., Stiewe, T., Parssanedjad, K., Rega, S., Esche, H., E1A is sufficient by itself to induce apoptosis independent of p53 and other adenoviral gene products (2000) Cell Death Differ, 7, pp. 177-188
Rothmann, T., Hengstermann, A., Whitaker, N.J., Scheffner, M., Zur Hausen, H., Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells (1998) J Virol, 72, pp. 9470-9478
Goodrum, F.D., Ornelles, D.A., p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lyric infection (1998) J Virol, 72, pp. 9479-9490
Wadler, S., Yu, B., Tan, J.Y., Kaleya, R., Rozenblit, A., Makower, D., Edelman, M., Horwitz, M., Persistent replication of the modified chimeric adenovirus ONYX-015 in both tumor and stromal cells from a patient with gall bladder carcinoma implants (2003) Clin Cancer Res, 9, pp. 33-43
Ain, K. B., Anaplastic thyroid carcinoma: A therapeutic challenge (1999) Semin Surg Oncol, 16, pp. 64-69
Bischott, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., McCormick, F., An adenovirus mutant that replicates selectively in p53 deficient human tumor cells (1996) Science, 274, pp. 373-376
Ries, S. J., Brandts, C. H., Chung, A. S., Biederer, C. H., Hann, B. C., Lipner, E. M., McCormick, F., Korn, W. M., Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015) (2000) Nat Med, 6, pp. 1128-1133
Fagin, J. A., Matsuo, K., Karmakar, A., Chen, D. L., Tang, S. H., Koeffler, H. P., High prevalence of mutations of p53 gene in poorly differentiated human thyroid carcinomas (1993) J Clin Invest, 91, pp. 179-184
Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Kirn, D. H., A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer patients (2000) Nat Med, 6, pp. 879-885
Habib, N. A., Mitry, R. R., Sarraf, C. E., Habib, N. A., Mitry, R. R., Sarraf, C. E., Jiao, L. R., Jensen, S. L., Assessment of growth inhibition and morphological changes in in vitro and in vivo hepatocellular carcinoma models post treatment with dl1520 adenovirus (2002) Cancer Gene Ther, 9, pp. 414-420
Pang, X. J., Hershman, M., Chung, M., Pekary, A. E., Characterization of tumor necrosis factor- receptors in human and rat thyroid cells and regulation of the receptors by thyrotropin (1989) Endocrinology, 125, pp. 1783-1788
Ain, K. B., Tofiq, S., Taylor, K. D., Antineoplastic activity of taxol against human anaplastic thyroid carcinoma cell lines in vitro and in vivo (1996) J Clin Endocrinol Metab, 81, pp. 3650-3653
Rogulski, K. R., Freytag, S. O., Zhang, K., Gilbert, J. D., Paielli, D. L., Kim, J. H., Heise, C. C., Kirn, D. H., In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy (2000) Cancer Res, 60, pp. 1193-1196
Haigh, P. I., Anaplastic thyroid carcinoma (2000) Curr Treat Options Oncol, 1, pp. 353-357
Yeung, S. J., Xu, G., Pan, J., Christgen, M., Bamiagis, A., Manumycin enhances the cytotoxix effect of paclitaxel on anaplastic thyroid carcinoma cells (2000) Cancer Res, 60, pp. 650-656
Lowe, S. W., Ruley, H. E., Jacks, T., Housman, D. E., p53-Dependent apoptosis modulates the cytotoxicity of anticancer agents (1993) Cell, 74, pp. 957-967
Zhou, Z., Jia, S. F., Hung, M. C., Kleinerman, E. S., E1A sensitizes HER2/neu overexpressing Ewing's sarcoma cells to topoisomerase II-targeting anticancer drugs (2001) Cancer Res, 61, pp. 3394-3398
Putzer, B. M., Stiewe, T., Parssanedjad, K., Rega, S., Esche, H., E1A is sufficient by itself to induce apoptosis independent of p53 and other adenoviral gene products (2000) Cell Death Differ, 7, pp. 177-188
Goodrum, F. D., Ornelles, D. A., p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lyric infection (1998) J Virol, 72, pp. 9479-9490
ONYX-015 Enhances Radiation-Induced Death of Human Anaplastic Thyroid Carcinoma Cells
ONYX-015 is a genetically modified adenovirus with a deletion of the E1B early gene and therefore is designed to replicate preferentially in p53-mutated cells causing their death. We previously demonstrated that the ONYX-015 virus kills anaplastic thyroid carcinoma (ATC) cells and enhances the anti-neoplastic effects of doxorubicin and paclitaxel. Here we report that ONYX-015 increased the cytopathic effect of radiotherapy in three ATC cell lines. In fact, ONYX-015 and radiation induced a significant cytopathic effect on ATC cells. DNA fragmentation analysis showed that ATC ONYX-015-treated cells were very sensitive to radiation-induced apoptosis. In addition, low doses of ONYX-015 associated with a single radiation dose of 10 Gy delayed the growth of a xenograft tumor induced by ARO cells in athymic mice. Our results suggest that the combination of ONYX-015 and radiotherapy should be considered for experimental trials in patients with anaplastic thyroid carcinoma.
ONYX-015 Enhances Radiation-Induced Death of Human Anaplastic Thyroid Carcinoma Cells
No results.
ONYX-015 Enhances Radiation-Induced Death of Human Anaplastic Thyroid Carcinoma Cells